Xenomics Inc.'s Preliminary Investigation Leads the Company to Believe Sequenom Inc. Willfully Manipulated its Down Syndrome Data in its Presentations

NEW YORK--(BUSINESS WIRE)--Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular diagnostics, announced today that an ongoing internal investigation by Xenomics’ personnel of the events surrounding its licensing deal with Sequenom (Nasdaq:SQNM) in late October, 2008 leads it to conclude that Sequenom purposely misled the Company - fraudulently inducing Xenomics into granting Sequenom an exclusive license to its transrenal technology. Sequenom’s announced success in developing a Down Syndrome test in late 2008 was the principal factor in Xenomics’ decision to exclusively license its core Transrenal DNA and RNA technology in the area of fetal diagnostics to Sequenom.